Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Receivables (2021 - 2025)

Historic Receivables for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $51.7 million.

  • Kiniksa Pharmaceuticals International's Receivables rose 10789.94% to $51.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year increase of 10789.94%. This contributed to the annual value of $41.7 million for FY2024, which is 9620.05% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Receivables stood at $51.7 million for Q3 2025, which was up 10789.94% from $31.9 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Receivables registered a high of $51.7 million during Q3 2025, and its lowest value of $2.6 million during Q2 2021.
  • Its 5-year average for Receivables is $20.1 million, with a median of $20.4 million in 2022.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Receivables plummeted by 7478.26% in 2023, and later soared by 71841.5% in 2024.
  • Kiniksa Pharmaceuticals International's Receivables (Quarter) stood at $4.0 million in 2021, then skyrocketed by 409.81% to $20.3 million in 2022, then grew by 4.68% to $21.3 million in 2023, then soared by 96.2% to $41.7 million in 2024, then grew by 24.01% to $51.7 million in 2025.
  • Its Receivables stands at $51.7 million for Q3 2025, versus $31.9 million for Q2 2025 and $40.1 million for Q1 2025.